<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306446</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2013-1</org_study_id>
    <nct_id>NCT03306446</nct_id>
  </id_info>
  <brief_title>Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab</brief_title>
  <acronym>CURE</acronym>
  <official_title>Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with
      early CD. This study will not change the patient/physician relationship.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective will be to evaluate the sustained deep remission rate one year after
      discontinuation of a 12 month course of adalimumab in adult patients with early CD who have
      achieved deep remission at 12 months AND who were already in clinical remission (CDAI &lt; 150)
      and biomarker remission (CRP &lt; 5 mg/L and fecal calprotectin &lt; 250) at 6 months. The study
      will also address several questions:

        -  What is the rate of deep remission after a 12-month course of adalimumab in early CD
           patients?

        -  What is the rate of deep remission 12 months after adalimumab discontinuation in
           patients with deep remission after a 12-month course of adalimumab (thus defining
           sustained deep remission) AND who were already in clinical remission (CDAI &lt; 150) and
           biomarker remission (CRP &lt; 5 mg/L and fecal calprotectin &lt; 250) at 6 months?

        -  What are the consequences of a treatment with adalimumab on the natural course of CD and
           long-term clinical outcomes (bowel damage, CD related surgeries and hospitalization, and
           patient-reported outcomes)? Therefore the study will give information on the effect of a
           12-month course of adalimumab in early CD patients, impact of &quot;drug holiday&quot; after deep
           remission has been achieved, and long term effect of adalimumab on early CD course
           (relapses, CD-related surgery and hospitalizations, bowel damage, and patient-reported
           outcomes). The study will also assess predictors of loss of deep remission at 2-year
           evaluation in patients who achieved 1-year deep remission. Efficacy and tolerability of
           adalimumab will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained deep remission rate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with sustained deep remission at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year deep remission rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with 2-year deep remission rate among patients who did not achieve 1-year remission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of an early treatment with adalimumab on long-term clinical outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Frequency and severity of adverse events in patients followed for 5 years</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>CD</condition>
  <arm_group>
    <arm_group_label>Adalimumab in monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Start adalimumab in monotherapy</intervention_name>
    <description>Discontinuation of Adalimumab in patients who achieved deep remission</description>
    <arm_group_label>Adalimumab in monotherapy</arm_group_label>
    <other_name>begin humira in monotherapie in Early crohn disease patient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged 18 years old to 75 years old 2. Patient with early luminal
             Crohn's disease (less than 24 months since diagnosis), 3. Patient who is

          -  intolerant to immunosuppressants or steroids, or

          -  primarily not responders to immunosuppressants for at least 3 months [azathioprine: at
             least 2.5 mg/kg/d; 6-mercaptopurine: at least 1.5 mg/kg/d; methotrexate: 25 mg/week
             (subcutaneous or intramuscular route)], and/or

          -  not responder to steroids [prednisolone equivalent at least 40 mg/d], and/or

          -  steroid-dependent [unable to reduce corticosteroids below the equivalent of
             prednisolone 10 mg/d or budesonide &lt; 6 mg/d within 3 months of starting
             corticosteroids without recurrent active disease, or who have a relapse within 3
             months of stopping corticosteroids], 4. Patient with CDAI &gt; 150, 5. Patient with at
             least one ulcer in at least one affected segment (Magnetic Resonance Imaging (MRI) of
             gastrointestinal tract or colonoscopy or by video capsule conducted after failure of
             conventional therapy and within 12 weeks before inclusion in the study), 6. Patient
             naïve for anti-TNF, 7. Patient whose physician decides to start adalimumab as
             monotherapy independently from the study protocol, 8. Patient followed in a centre
             belonging to the GETAID network. 9. Written consent.

        Exclusion Criteria:

          -  Patient with active complex perianal fistula according to the definition of the
             American Gastroenterological Association (AGA) [high anal fistula, abscess, proctitis,
             multiple external openings],

          -  Patient with stoma,

          -  previous surgery in IBD

          -  Pregnant or breastfeeding women, absence of contraception

          -  Patient with any contra-indication to adalimumab.

          -  Patient with any contra-indication to MRI

          -  Minors and people unable to give their consent (because of their physical or mental
             state).

          -  Subject who has not given his/her consent to participate.

          -  Subject participating in another study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Bouhnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Peyrin-Biroulet, MD , PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaelle Brillault</last_name>
    <email>gbrillault@getaid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Liege</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CATHERINE REENAERS, MD</last_name>
    </contact>
    <contact_backup>
      <email>catherine.reenaers@chu.ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>EDOUARD LOUIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CATHERINE REENAERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN-LOUIS DUPAS, MD</last_name>
      <email>dupas.jean-louis@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>JEAN-LOUIS DUPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARTINE LECONTE</last_name>
    </contact>
    <contact_backup>
      <email>Leconte.Martine@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>JEAN LOUIS DUPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MATHURIN FLAMANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU BESANCON- Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUCINE VUITTON, MD</last_name>
      <email>lvuitton@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>LUCINE VUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAPHAELLE BLONBET</last_name>
    </contact>
    <contact_backup>
      <email>rblondet@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LUCINE VUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen- Hopital de la Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEPHANIE VIENNOT, MD</last_name>
      <email>viennot-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>STEPHANIE VIENNOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de CLERMONT FERRAND- Hopital Estain</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GILLES BOMMELAER, MD</last_name>
      <email>gbommelaer@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>GILLES BOMMELAER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital BEAUJON</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <email>yoram.bouhnik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>CARMEN STEFANESCU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Colmar- Hopital Trousseau Medecine A</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURIANNE PLASTARAS, MD</last_name>
      <email>laurianne.plastaras@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>LAURIANNE PLASTARAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille- Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARIA NACHURY, PU-PH</last_name>
      <email>maria.nachury@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>MARIA NACHURY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CATHERINE CUNISSE</last_name>
    </contact>
    <contact_backup>
      <email>catherine.cunisse@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>MARIA NACHURY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BENJAMIN PARIENTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier- Hopital saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLAUME PINTON DE CHAMBRUHN</last_name>
      <email>gpinetondechambrun@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>PIERRE BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUILLAUME PINTON DE CHAMBRUHN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ROMAIN ALTWEGG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes- Hopital HOTEL DIEU</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ARNAUD BOURREILLE, MD</last_name>
      <email>arnaud.bourreille@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>ARNAUD BOURREILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANTES - Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELISE KERDREUX</last_name>
      <email>Elise.KERDREUX@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>ARNAUD BOURREILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de NICE- Hopital Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEROME FILLIPI, MD</last_name>
      <email>filippi.j@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>JEROME FILLIPI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XAVIER HEBUTERNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes- Hopital Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUDOVIC CAILLO, MD</last_name>
      <email>Ludovic.CAILLO@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>LUDOVIC CAILLO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital BICHAT</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANNE-LAURE PELLETIER, MD</last_name>
      <email>anne-laure.pelletier@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>ANNE-LAURE PELLETIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMM</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARION SIMON, MD</last_name>
      <email>marion.simon@imm.fr</email>
    </contact>
    <investigator>
      <last_name>MARION SIMON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux- Hopital Haut Levèque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID LAHARIE, MD</last_name>
    </contact>
    <contact_backup>
      <email>david.laharie@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>DAVID LAHARIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU LYON- Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEPHANE NANCEY, MD</last_name>
      <email>stephane.nancey@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>STEPHANE NANCEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU RENNES - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
    </contact>
    <contact_backup>
      <email>guillaume.bouguen@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIE DEWITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne- Hopital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XAVIER ROBLIN, MD</last_name>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>XAVIER ROBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARIANNE LASSAILLY</last_name>
      <email>lassailly.m@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>JACQUES MOREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CYRIELLE GILLETTA DE SAINT JOSEPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ASTRID STALTER, ARC</last_name>
    </contact>
    <investigator>
      <last_name>LAURENCE PICON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ALEXANDRE AUBOURG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hopital Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURENT PEYRIN BIROULET, MD,PhD</last_name>
      <phone>+33383153354</phone>
      <email>peyrinbiroulet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laurent PEYRIN-BIROULET, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille ZALLOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

